Petlife Pharmaceuticals, Inc. (PTLF)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: May 23, 2025
Petlife Pharmaceuticals Company Description
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States.
The company’s principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor.
In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.
Petlife Pharmaceuticals, Inc.
| Country | United States |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Sebastian Serrell-Watts |
Contact Details
Address: 8033 Sunset Boulevard Los Angeles, Nevada 90046 United States | |
| Phone | 424-216-6807 |
Stock Details
| Ticker Symbol | PTLF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | September - August |
| Reporting Currency | USD |
| ISIN Number | US71639C1036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sebastian Serrell-Watts | Chairman, Chief Executive Officer, President, Chief Financial Officer, Secretary and Treasurer |
| Dr. Arthur Grant Mikaelian Ph.D. | Founder and Chief Scientific Officer |